Antibiotic strategies and clinical outcomes in critically ill patients with pneumonia caused by carbapenem-resistant Acinetobacter baumannii

Kuo, 2012, Emergence of extensively drug-resistant Acinetobacter baumannii complex over 10 years: nationwide data from the Taiwan Surveillance of Antimicrobial Resistance (TSAR) program, BMC Infect Dis, 12, 200, 10.1186/1471-2334-12-200 Turner, 2008, Meropenem activity against European isolates: report on the MYSTIC (meropenem yearly susceptibility test information collection) 2006 results, Diagn Microbiol Infect Dis, 60, 185, 10.1016/j.diagmicrobio.2007.09.006 Gales, 2011, Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: results from the SENTRY Antimicrobial Surveillance Program (2006–09), J Antimicrob Chemother, 66, 2070, 10.1093/jac/dkr239 Willyard, 2017, The drug-resistant bacteria that pose the greatest health threats, Nature, 543, 15, 10.1038/nature.2017.21550 Lemos, 2014, Carbapenem resistance and mortality in patients with Acinetobacter baumannii infection: systematic review and meta-analysis, Clin Microbiol Infect, 20, 416, 10.1111/1469-0691.12363 Kim, 2012, Risk factors for occurrence and 30-day mortality for carbapenem-resistant Acinetobacter baumannii bacteremia in an intensive care unit, J Korean Med Sci, 27, 939, 10.3346/jkms.2012.27.8.939 Liu, 2016, Risk factors of mortality in patients with carbapenem-resistant Acinetobacter baumannii bacteremia, J Microbiol Immunol Infect, 49, 934, 10.1016/j.jmii.2014.10.006 Center for disease control ROC (Taiwan), 2015 Doi, 2015, Acinetobacter baumannii: evolution of antimicrobial resistance-treatment options, Semin Respir Crit Care Med, 36, 85, 10.1055/s-0034-1398388 Lin, 2014, Antimicrobial resistance in Acinetobacter baumannii: from bench to bedside, World J Clin Cases, 2, 787, 10.12998/wjcc.v2.i12.787 2010 Evans, 1999, Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria, Ann Pharmacother, 33, 960, 10.1345/aph.18426 Khawcharoenporn, 2014, Colistin-based treatment for extensively drug-resistant Acinetobacter baumannii pneumonia, Int J Antimicrob Agents, 43, 378, 10.1016/j.ijantimicag.2014.01.016 Temocin, 2015, Synergistic effects of sulbactam in multi-drug-resistant Acinetobacter baumannii, Braz J Microbiol, 46, 1119, 10.1590/S1517-838246420140101 Kalin, 2014, Comparison of colistin and colistin/sulbactam for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia, Infection, 42, 37, 10.1007/s15010-013-0495-y Zusman, 2017, Polymyxin monotherapy or in combination against carbapenem-resistant bacteria: systematic review and meta-analysis, J Antimicrob Chemother, 72, 29, 10.1093/jac/dkw377 Horan, 2008, CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting, Am J Infect Control, 36, 309, 10.1016/j.ajic.2008.03.002 Magiorakos, 2012, Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance, Clin Microbiol Infect, 18, 268, 10.1111/j.1469-0691.2011.03570.x Breakpoint tables for interpretation of MICs and zone diameters [Internet], 2016 Charlson, 1987, A new method of classifying prognostic comorbidity in longitudinal studies: development and validation, J Chronic Dis, 40, 373, 10.1016/0021-9681(87)90171-8 Knaus, 1985, APACHE II: a severity of disease classification system, Crit Care Med, 13, 818, 10.1097/00003246-198510000-00009 David, 2016 Ni, 2016, Tigecycline treatment experience against multidrug-resistant Acinetobacter baumannii infections: a systematic review and meta-analysis, Int J Antimicrob Agents, 47, 107, 10.1016/j.ijantimicag.2015.11.011 Chuang, 2014, Effectiveness of tigecycline-based versus colistin-based therapy for treatment of pneumonia caused by multidrug-resistant Acinetobacter baumannii in a critical setting: a matched cohort analysis, BMC Infect Dis, 14, 102, 10.1186/1471-2334-14-102 Chen, 2015, Meta-analysis of colistin for the treatment of Acinetobacter baumannii infection, Sci Rep, 5, 17091, 10.1038/srep17091 Chu, 2013, Sulbactam-based therapy for Acinetobacter baumannii infection: a systematic review and meta-analysis, Braz J Infect Dis, 17, 389, 10.1016/j.bjid.2012.10.029 Zalts, 2016, Treatment of carbapenem-resistant acinetobacter baumannii ventilator-associated pneumonia: retrospective comparison between intravenous colistin and intravenous ampicillin-sulbactam, Am J Ther, 23, e78, 10.1097/MJT.0b013e3182a32df3 Lo-Ten-Foe, 2007, Comparative evaluation of the VITEK 2, disk diffusion, etest, broth microdilution, and agar dilution susceptibility testing methods for colistin in clinical isolates, including heteroresistant Enterobacter cloacae and Acinetobacter baumannii strains, Antimicrob Agents Chemother, 51, 3726, 10.1128/AAC.01406-06 Kalil, 2016, Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society, Clin Infect Dis, 63, e61, 10.1093/cid/ciw353